Ken Griffin Revolution Medicines, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$36.92 - $47.94 $132,912 - $172,584	-3,600 Reduced 25.17%	10,700 $484,000
Q2 2024 Aug 14, 2024	SELL	$30.14 - $40.68 $208,297 - $281,139	-6,911 Reduced 32.58%	14,300 $554,000
Q1 2024 May 15, 2024	SELL	$26.56 - $33.55 $672,525 - $849,519	-25,321 Reduced 54.42%	21,211 $683,000
Q4 2023 Feb 14, 2024	BUY	$18.35 - $34.12 $626,322 - $1.16 Million	34,132 Added 275.26%	46,532 $1.33 Million
Q3 2023 Nov 14, 2023	BUY	$25.17 - $35.05 $5,034 - $7,009	200 Added 1.64%	12,400 $343,000
Q2 2023 Aug 14, 2023	BUY	$20.28 - $27.0 $101,400 - $135,000	5,000 Added 69.44%	12,200 $326,000
Q1 2023 May 15, 2023	BUY	$20.76 - $30.09 $101,724 - $147,441	4,900 Added 213.04%	7,200 $155,000
Q4 2022 Feb 14, 2023	SELL	$17.68 - $25.53 $929,968 - $1.34 Million	-52,600 Reduced 95.81%	2,300 $54,000
Q3 2022 Nov 14, 2022	BUY	$17.46 - $26.0 $958,554 - $1.43 Million	54,900 New	54,900 $1.08 Million

267

161M

260K

620K

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $5.07B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.